Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance

Tyrosine kinase inhibitors (TKIs) that primarily target angiogenesis are approved to treat several cancers in the metastatic setting; however, resistance is common. Sequential treatment or ‘switching’ from one TKI to another following failure can be effective, but predicting which drugs will have cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolan, Melissa, Mastri, Michalis, Tracz, Amanda, Christensen, James G., Chatta, Gurkamal, Ebos, John M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675057/
https://www.ncbi.nlm.nih.gov/pubmed/31369645
http://dx.doi.org/10.1371/journal.pone.0220101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675057/
https://www.ncbi.nlm.nih.gov/pubmed/31369645
http://dx.doi.org/10.1371/journal.pone.0220101

Ejemplares similares